Smruthi Organics Limited
BSE: SMRUTHIORG · Pharmaceuticals · sector
₹134.45BSE close 2026-10-26
Key numbers
Market cap₹154 cr
Price₹134.45
52w high / low₹175 / ₹95
P/E20.8xSector median 27.9x
P/B2.1xSector median 2.9x
Book value₹64.2
Dividend yield1.11%Sector median 0.48%
ROE10.2%Sector median 11.7%
ROCE14.3%Sector median 12.3%
OPM16.2%Sector median 14.0%
Debt / equity0.11xSector median 0.16x
EV/EBITDA8.8xSector median 18.6x
Interest cover7.6x
Current ratio1.98x
Sales growth 3y-10.2%Sector median +9.6%
Profit growth 3y-6.0%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2 cr vs borrowings ₹8 cr (FY26): borrowings are higher by ₹6 cr.
- Operating profit covered interest 7.6x in the last 12 months.
- Net loss in 1 of the last 6 quarters.
- Other income was 1% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹134.45 on 2026-10-26: -23.3% from the 52-week high, +41.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹168.80 · low ₹101.99
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 38 | 19 | 32 | 22 | 29 | 29 |
| EBITDA | 5 | 0 | 5 | 4 | 4 | 6 |
| OPM % | 12.3% | 1.2% | 15.9% | 15.9% | 13.0% | 19.9% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 2 | -1 | 2 | 1 | 1 | 3 |
| EPS (₹) | 1.95 | 0.96 | 1.80 | 1.22 | 0.93 | 2.51 |
| Revenue YoY | -23.6% | +54.3% | ||||
| Profit YoY | -52.0% | – |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 133 | 141 | 128 | 126 | 102 | 112 |
| EBITDA | 18 | 10 | 12 | 12 | 13 | 18 |
| Net profit | 10 | 4 | 4 | 4 | 3 | 7 |
| EPS (₹) | 9.07 | 3.87 | 3.14 | 3.11 | 2.99 | 6.46 |
| Revenue growth | +5.8% | -9.5% | -1.3% | -19.1% | – | |
| Profit growth | -60.2% | -13.1% | -0.8% | -3.7% | – | |
| Dividend / share (₹) | – | 3.00 | 2.00 | 1.50 | 1.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -10.2% | – | – |
| Net profit | -6.0% | – | – |
| EPS | -8.2% | – | – |
| Share price | – | +2.1% (2y) | -0.3% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 72 | 74 |
| Borrowings | 17 | 8 |
| Cash & equivalents | 1 | 2 |
| Total assets | 112 | 104 |
| Fixed assets | 45 | 47 |
| Capital work in progress | 3 | 3 |
| Investments | 0 | 0 |
| Receivables | 32 | 19 |
| Inventory | 28 | 28 |
| Payables | 16 | 14 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 10 | 22 |
| Cash from investing | -11 | -9 |
| Cash from financing | 1 | -12 |
| Capex | 12 | 8 |
| Free cash flow | -2 | 14 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 5.0% | 4.7% |
| ROCE % | 7.7% | 7.8% |
| Debtor days | 94 | 69 |
| Inventory days | 151 | 228 |
| Payable days | 85 | 111 |
| Cash conversion cycle (days) | 160 | 186 |
| Working capital days | 93 | 93 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SMRUTHIORG | ₹154 cr | 20.8x | 2.1x | 10.2% | 14.3% | 16.2% | -10.2% | 1.11% |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| API | ₹29 cr | 100.0% | ₹4 cr | 14.3% |
| Formulation | ₹0 cr | – | ₹-0 cr | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-07-31 | Dividend | Dividend Rs 1.5 |
| 2025-06-13 | Dividend | Final Dividend Rs 1.5 |
| 2024-09-06 | Dividend | Final Dividend Rs 1.5 |
| 2023-07-28 | Dividend | Final Dividend Rs 2.0 |
| 2022-07-28 | Dividend | Dividend Rs 3.0 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SMRUTHIORG |
| BSE code | 540686 |
| ISIN | INE172E01011 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.